Drug Database · Clinicians

Bilastine

Brands (15) Bilaxten, Balstimax, Bilasmin…Show all

Antihistamine PH FDA category

Rx · Prescription drug18 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Contraindications

  • Hypersensitivity
renalcarematters.com, reviewed

Dosing: Adult

  • Allergic rhinoconjunctivitis and urticaria (adults and adolescents 12 years and older): 20 mg once daily, 1 hour before or 2 hours after food or fruit juice
renalcarematters.com, reviewed

Dosing: Altered kidney function

Bilastine is a non-sedating antihistamine that is not metabolized; about 28% is excreted unchanged in urine. Exposure rises about 2.3-fold in severe kidney impairment, but the European label needs no dose change in adults. It advises avoiding P-glycoprotein inhibitors (such as ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem) in moderate or severe kidney impairment. It has no US FDA label.

Kidney function measure: SmPC pharmacokinetic groups use glomerular filtration rate (GFR, mL/min/1.73 m2); no dose adjustment at any level. Bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Usual: 20 mg once daily, 1 hour before or 2 hours after food or fruit juice (SmPC).
CrCl 30–59 mL/min
No dose adjustment (SmPC). Moderate impairment: avoid P-glycoprotein inhibitors (ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem).
CrCl 15–29 mL/min
No dose adjustment (SmPC); AUC about 2.3-fold higher in severe impairment. Avoid P-glycoprotein inhibitors.
CrCl <15 mL/min (not on dialysis)
No dose adjustment (SmPC). Avoid P-glycoprotein inhibitors.
Hemodialysis (intermittent)
Not studied in dialysis (SmPC silent). No adjustment in severe impairment; avoid P-glycoprotein inhibitors.
Peritoneal dialysis
Not studied in dialysis.
CRRT
Not studied.
  • Dialyzable? Not stated (84% to 90% protein-bound).
  • Monitoring QT risk factors (hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, QT-prolonging drugs) (SmPC 4.4).
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Normal kidney function: usual pediatric dose (SmPC).
eGFR 30–59
Safety and efficacy in children with kidney impairment not established (SmPC).
eGFR 15–29
Safety and efficacy in children with kidney impairment not established (SmPC).
eGFR <15 (not on dialysis)
Safety and efficacy in children with kidney impairment not established (SmPC).
Hemodialysis (intermittent)
Not established in children.
Peritoneal dialysis
Not established in children.
CRRT
Not established in children.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: HPRA (Ireland) product information (February 2026). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
2 years and older, weighing at least 15 kg (SmPC).
Usual dose
2 to 11 years (15 kg or more): 10 mg once daily (orodispersible tablet or oral solution). 12 years and older: 20 mg once daily.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Tablet: 20 mg
  • Oral solution: 2.5 mg/mL
  • Orodispersible tablet: 10 mg

Registered products in the Philippines

18 products registered with the Food and Drug Administration (FDA) Philippines list Bilastine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products18
Philippine FDA-registered products for Bilastine
Package insert
BalstimaxBilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
One Technodrug Life Sciences Inc.Importer: Ambica International Corporation
DRP-14872-02
Jan 26, 2029
BilasminBilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Vamsler Phils. Inc.Importer: Ambica International Corporation
DRP-14872-08
Jan 26, 2029
BILASYNBilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Glorious Dexa Mandaya, Inc.Importer: Ambica International Corporation
DRP-14872-09
Jan 26, 2029
BilatrisBilastine
20 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
Rx
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-19006
Oct 19, 2031
BilaxtenBilastine
10 mg Orodispersible TabletAlu/Alu Blister Pack X 10'S(Box of 10's 20's 30's and 50's)
Rx
A. Menarini Manufacturing Logistics and Services S.r.I.Italy
A. Menarini Philippines
DR-XY47344
Feb 2, 2031
BilaxtenBilastine
2.5mg/mL Oral SolutionAmber glass bottle (120mL net content) with polypropylene cap and LDPE liner + 25 mL measuring cup (Box of 1's)
Rx
Berlin-Chemie AGGermany
A. Menarini Philippines, Inc.
DR-XY48085
Jun 2, 2027
BilaxtenBilastine
20 mg TabletAlu-Alu blister pack Box of 10's; Alu-Alu blister pack Box of 20's; Alu-Alu blister pack Box of 30's; Alu-Alu blister pack Box of 40's; Alu-Alu blister pack Box of 50's; Alu-Alu blister pack Box of 4's (Physician's sample)
Rx
A. Menarini Manufacturing Logistics And Services S.R.LItaly
Importer: A.MENARINI PHILIPPINES, INC.
DR-XY43523
Jul 7, 2029
BilfastBilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: Ambica International Corporation
DRP-14872-05
Jan 26, 2029
BilphilBilastine
20 mg TabletAlu/Alu Blister Pack X 10's (Box of 30's)
Rx
Exemed PharmaceuticalsIndia
AMB HK Enterprises, Inc.
DRP-18901
Sep 29, 2031
Bilwin 20Bilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-14872
Jan 26, 2029
BlastnicBilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Maed Pharma CorporationImporter: Ambica International Corporation
DRP-14872-03
Jan 26, 2029
BlazenBilastine
20 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ajanta Pharma Philippines Inc.Importer: Ambica International Corporation
DRP-14872-01
Jan 26, 2029
BreezalinBilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-14872-04
Jan 26, 2029
BrilixBilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Pro Medica Inc.Importer: Ambica International Corporation
DRP-14872-07
Jan 26, 2029
BylastBilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: Ambica International Corporation
DRP-14872-10
Jan 26, 2029
LaxitinBilastine
20 mg TabletAlu/Alu Blister Pack x 10’s (Box of 50’s)
Rx
Vivimed Labs Ltd.India
Hexagon Pharmaceuticals
DRP-18633
Aug 11, 2031
NadrizarBilastine
20 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Magbro Healthcare Pvt. Ltd.India
Pharmakon Biotec Inc.
DRP-18767
Sep 3, 2031
NoneBilastine
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
South Star DrugImporter: Ambica International Corporation
DRP-14872-06
Jan 26, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
P-glycoprotein inhibitors (ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem)AvoidBilastine AUC up 2-fold, peak up 2- to 3-fold (ketoconazole, erythromycin).Avoid in moderate or severe kidney impairment; no action needed with normal kidney function.
Food, grapefruit and other fruit juicesMinorBioavailability falls about 30%.Take 1 hour before or 2 hours after.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Headache (4.0%)
  • Somnolence (3.1%)
  • Dizziness, fatigue

Serious

  • QT prolongation (reported)
renalcarematters.com, reviewed

Monitoring parameters

  • QT risk factors (hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, QT-prolonging drugs) (SmPC 4.4). Kidney
  • QT risk factors in susceptible patients
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Bioavailability61%
Time to peakAbout 1.3 hours
Half-life14.5 hours
Half-life in kidney failure (ESKD) kidney18.4 hours in severe impairment (GFR <30) vs 9.3 hours normal; AUC 1,708.5 vs 737.4 ng·h/mL
Protein binding84% to 90%
Metabolism (CYP, transporters)Not significantly metabolized
Active metabolitesNone
Renal excretion kidney28.3% unchanged in urine; 66.5% in feces
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Health Products Regulatory Authority (Ireland). Drynol 20 mg tablets SmPC (PA0865/018/001) [HPRA (Ireland) product information, February 2026; no US FDA label]. https://assets.hpra.ie/products/Human/22434/Licence_PA0865-018-001_25022026171031.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Menarini International Operations Luxembourg S.A.. (2026). Drynol 20 mg tablets (bilastine) [Summary of product characteristics, licence PA0865/018/001; text revised February 2026]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/22434/Licence_PA0865-018-001_25022026171031.pdf

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .